Ala'a Alkerwi

COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a multicentre cohort study using electronic health registries in six European countries, 2021 to 2022.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: February 28, 2025

Widening the scope for the burden of COVID-19 - Comorbidities and long COVID: an analysis of the three pandemic years in Luxembourg.

Journal: European review for medical and pharmacological sciences

Published: February 06, 2025

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: January 05, 2024

Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.

Journal: Influenza and other respiratory viruses

Published: May 27, 2023

Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices.

Journal: Epidemiology and infection

Published: January 09, 2023

Conducting national burden of disease studies and knowledge translation in eight small European states: challenges and opportunities.

Journal: Health research policy and systems

Published: May 11, 2022

Methodological considerations in injury burden of disease studies across Europe: a systematic literature review.

Journal: BMC public health

Published: April 05, 2022

Population-based biomonitoring of exposure to persistent and non-persistent organic pollutants in the Grand Duchy of Luxembourg: Results from hair analysis.

Journal: Environment international

Published: January 27, 2021

Objective and subjective sleep measures are associated with HbA1c and insulin sensitivity in the general population: Findings from the ORISCAV-LUX-2 study.

Journal: Diabetes & metabolism

Published: November 06, 2020

Mapping the burden of diabetes in five small countries in Europe and setting the agenda for health policy and strategic action.

Journal: Health research policy and systems

Published: October 13, 2020

Conducting national burden of disease studies in small countries in Europe- a feasible challenge?

Journal: Archives of public health = Archives belges de sante publique

Published: April 21, 2020

Challenges and benefits of integrating diverse sampling strategies in the observation of cardiovascular risk factors (ORISCAV-LUX 2) study.

Journal: BMC medical research methodology

Published: June 18, 2018

COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a multicentre cohort study using electronic health registries in six European countries, 2021 to 2022.

COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a multicentre cohort study using electronic health registries in six European countries, 2021 to 2022.

Widening the scope for the burden of COVID-19 - Comorbidities and long COVID: an analysis of the three pandemic years in Luxembourg.

Widening the scope for the burden of COVID-19 - Comorbidities and long COVID: an analysis of the three pandemic years in Luxembourg.

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.

Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.

Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices.

Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices.

Conducting national burden of disease studies and knowledge translation in eight small European states: challenges and opportunities.

Conducting national burden of disease studies and knowledge translation in eight small European states: challenges and opportunities.

Methodological considerations in injury burden of disease studies across Europe: a systematic literature review.

Methodological considerations in injury burden of disease studies across Europe: a systematic literature review.

Population-based biomonitoring of exposure to persistent and non-persistent organic pollutants in the Grand Duchy of Luxembourg: Results from hair analysis.

Population-based biomonitoring of exposure to persistent and non-persistent organic pollutants in the Grand Duchy of Luxembourg: Results from hair analysis.

Objective and subjective sleep measures are associated with HbA1c and insulin sensitivity in the general population: Findings from the ORISCAV-LUX-2 study.

Objective and subjective sleep measures are associated with HbA1c and insulin sensitivity in the general population: Findings from the ORISCAV-LUX-2 study.

Mapping the burden of diabetes in five small countries in Europe and setting the agenda for health policy and strategic action.

Mapping the burden of diabetes in five small countries in Europe and setting the agenda for health policy and strategic action.

Conducting national burden of disease studies in small countries in Europe- a feasible challenge?

Conducting national burden of disease studies in small countries in Europe- a feasible challenge?

Challenges and benefits of integrating diverse sampling strategies in the observation of cardiovascular risk factors (ORISCAV-LUX 2) study.

Challenges and benefits of integrating diverse sampling strategies in the observation of cardiovascular risk factors (ORISCAV-LUX 2) study.

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.